{"filing":{"accession_number":"0001193125-26-304033","cik":"0000893949","ticker":"MD","company_name":"Pediatrix Medical Group, Inc.","form":"8-K","filing_date":"2026-07-15","report_date":null,"primary_document":"md-20260715.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/893949/000119312526304033/md-20260715.htm"},"events":[{"id":18006,"run_id":16160,"accession_number":"0001193125-26-304033","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Pediatrix issued a press release on July 15, 2026 providing a second quarter 2026 business update, reaffirming full-year 2026 Adjusted EBITDA guidance of $280–$300 million and confirming stable payor mix and revenue trends. The company also announced a detailed earnings conference call for August 4, 2026.","company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","filing_date":"2026-07-15","form":"8-K","submitted_at":null,"items":[{"id":16686,"accession_number":"0001193125-26-304033","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Pediatrix issued a press release on July 15, 2026 providing a second quarter 2026 business update, reaffirming full-year 2026 Adjusted EBITDA guidance of $280–$300 million and confirming stable payor mix and revenue trends. Although styled as an \"update\" rather than full quarterly results, the disclosure includes forward-looking financial guidance with a reconciliation table and is furnished under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The company also announced a detailed earnings conference call for August 4, 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T11:01:41.143992+00:00","company_name":"","ticker":null,"filing_date":""},{"id":16687,"accession_number":"0001193125-26-304033","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.72,"reasoning":"This is a business update and guidance reaffirmation furnished under Item 7.01 (Regulation FD Disclosure). The company confirms stable payor mix trends and reaffirms its full-year 2026 Adjusted EBITDA guidance of $280–$300 million. While the disclosure addresses operational trends (payor mix, revenue trends) and provides forward guidance, it does not constitute a formal earnings release (which would typically be Item 2.02 with full quarterly results) nor does it disclose a material operational event like a restructuring, contract, or strategic milestone. The update is primarily reassurance to investors regarding business stability in light of sector-wide concerns.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T11:01:41.143992+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16686,"accession_number":"0001193125-26-304033","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Pediatrix issued a press release on July 15, 2026 providing a second quarter 2026 business update, reaffirming full-year 2026 Adjusted EBITDA guidance of $280–$300 million and confirming stable payor mix and revenue trends. Although styled as an \"update\" rather than full quarterly results, the disclosure includes forward-looking financial guidance with a reconciliation table and is furnished under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The company also announced a detailed earnings conference call for August 4, 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T11:01:41.143992+00:00","company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","filing_date":"2026-07-15"},{"id":16687,"accession_number":"0001193125-26-304033","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":false,"confidence":0.72,"reasoning":"This is a business update and guidance reaffirmation furnished under Item 7.01 (Regulation FD Disclosure). The company confirms stable payor mix trends and reaffirms its full-year 2026 Adjusted EBITDA guidance of $280–$300 million. While the disclosure addresses operational trends (payor mix, revenue trends) and provides forward guidance, it does not constitute a formal earnings release (which would typically be Item 2.02 with full quarterly results) nor does it disclose a material operational event like a restructuring, contract, or strategic milestone. The update is primarily reassurance to investors regarding business stability in light of sector-wide concerns.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T11:01:41.143992+00:00","company_name":"Pediatrix Medical Group, Inc.","ticker":"MD","filing_date":"2026-07-15"}]}